Strongly agree (unfortunately). The docs don't need 2+ reps with same products. Even if I was the only rep calling on them with my products, outside of first year after launch of a novel new product when you have a lot of new clinical data, they didn't need just me there at the frequency the company thought was needed. Most of us knew that well before covid.
we got the axe quickly in part because Laying off a contact sales team doesn't hit the press like it would AstraZenca lay-offs of 1,000 employees would go viral - and therefore impacting the stock price. Since the higher ups at most pharma companies not only likely have stock as a part of compensation - but as a big calculator for their year end bonus, my opinion is that's why there haven't been more layoffs across the industry yet. They keep hoping covid will vanish and things can go back to normal. Sadly, for the world not just pharma, it's not looking like that will happen anytime soon.